Project Grant HT9425261E117
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $1,062,400 project grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective November 1, 2025, through October 31, 2029. The award supports research to identify NEK5 as a hidden driver in kidney cancer, advancing biomedical innovations relevant to military health priorities and public health objectives. As a leading academic...
- Federal Grant Award Summary The University of Texas Southwestern Medical Center received a $1.476 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded on August 15, 2025, with a completion date of August 14, 2028. This award supports the development and research of an in situ tumor vaccine designed to stimulate antitumor immunity against breast cancer. The three-year project will be conducted at UT...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $319,800 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective November 1, 2025, through October 31, 2028. The award funds research on novel hypoxia-inducible factor 2 (HIF-2) regulators and therapeutic targets for kidney cancer, conducted at the institution's Dallas, Texas campus. This research initiative...
- Federal Grant Award Summary The University of Texas Southwestern Medical Center received a $323,700 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective November 1, 2025, through October 31, 2028. This award supports research utilizing enhancer CRISPR screening to identify PLXNA1 as a critical regulator in clear cell renal cell carcinoma (ccRCC). The research represents a translational science initiative aligned...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $1,311,922 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period September 1, 2025, through August 31, 2028. The project, titled "Next-Generation RCC Mouse Models Reproducing Human Oncogenotypes to Advance Therapeutics," supports advanced biomedical research focused on developing innovative animal models...
- Federal Grant Award Summary The University of Texas Southwestern Medical Center received a $450,174 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period September 1, 2025, through August 31, 2030. This award, titled "Building on the Foundation of the Academy of Kidney Cancer Investigators," supports biomedical research initiatives focused on kidney cancer investigation. The Military Medical...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $319,693 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective May 1, 2025 through July 31, 2027. The award supports research focused on dissecting the mechanism of selective HIF-2 regulation of PTHRP and hypercalcemia in clear cell renal carcinoma. This biomedical research project aims to advance understanding of...
- Summary of Federal Grant Award The University of Texas Southwestern Medical Center (UT Southwestern) received a $1.23 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for a four-year period beginning August 1, 2025 and concluding July 31, 2029. The award supports research focused on "Imaging Strategies and Biomarkers for Detecting the Metabolic Interplay of Glutamine and Aspartate in Renal Cell Carcinoma...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $700,000 to The University of Texas Health Science Center at San Antonio under the Military Medical Research and Development program (CFDA 12.420) effective June 1, 2026, through May 31, 2030. This project grant supports hypothesis-driven biomedical research investigating the relationship between epithelial mutations and exhausted T cells in creating a tumor-prone niche for endometriosis-associated ovarian cancer...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center was awarded $493,020 by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the project "Targeting WNK1 to Disrupt Cell Volume Control in Triple-Negative Breast Cancer." The award is effective July 1, 2026, through June 30, 2029. This project grant funds hypothesis-driven biomedical research designed to develop innovative therapeutic...
The University of Texas Southwestern Medical Center received a $1,049,994 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective June 1, 2026 through May 31, 2029. The award supports research investigating the therapeutic potential of detecting and inhibiting cytosolic ADP-ribosylation in ovarian cancer. This three-year research initiative aligns with the Military Medical Research and Development program's mission to support hypothesis-driven biomedical research that transforms healthcare for service members and the American public through innovative medical solutions addressing critical health challenges, with particular emphasis on oncology and cancer research. The research will be conducted at UT Southwestern's Dallas, Texas campus and is expected to deliver translational research outputs, biomarker discovery, and therapeutic development activities related to ovarian cancer treatment mechanisms. As a leading academic medical center with demonstrated capacity in federal research partnerships, UT Southwestern will leverage its biomedical research infrastructure and clinical expertise to advance understanding of ADP-ribosylation pathways as potential therapeutic targets in ovarian cancer treatment.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.0m | 4/16/26 |